SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 198.02-1.4%Jan 26 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tdinovo who wrote (10133)10/25/1997 9:47:00 PM
From: james  Read Replies (1) of 32384
 
Hi! tdinovo. I don't short stocks

I've been working in biotech since I got a job, which is 15 years ago. I've seen lots of them going down, lots of them going nowhere, and a few of them make it.

Drugs for metabolic diseases are extremely difficult to get through phase III, esp. for chronical usage. Its emphasis of longterm safety over efficacy kills >80% of them. If Ligand put 10 into trial (which only LLy can afford), and they all come from the same class but with different pharm. profile, I might change my mind. Nobody plays the market with 20% chance of one. You might know somemore details of their deal with LLY. I will glad to hear about it.

In the world of drug development, Glaxo & Pfizer are held with the highest regarded, Merck & Ciga., are so good as anybody. Their goals are two drugs/year at the best. Have you checked LLY's pipeline lately. Quite empty! Even Bayer got involved with mAB against TNF-alpha for sepsis, & failured. Quite desperated!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext